Assessment of carboprost tromethamine for reducing hemorrhage in laparoscopic intramural myomectomy

  • Authors:
    • Ruitao Zhang
    • Huirong Shi
    • Fang Ren
    • Zhongfu Yuan
  • View Affiliations

  • Published online on: July 20, 2015     https://doi.org/10.3892/etm.2015.2649
  • Pages: 1171-1174
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the effect of carboprost tromethamine on blood loss during laparoscopic myomectomy (LM) in females. Ninety women, who were scheduled for LM due to symptomatic uterine myomas, were randomly divided into three groups. Twenty‑four women were intramyometrially injected with 12 IU diluted vasopressin (vasopressin group), 30 cases received a deep intramuscular injection of 250 µg carboprost tromethamine 30 min prior to myomectomy (carboprost group), and 36 cases received an intramuscular injection of 250 µg carboprost tromethamine followed by a 20 IU oxytocin intravenous infusion at a rate of 120 mU/min during the procedure (carboprost plus oxytocin group). The procedure time, amount of hemorrhage, postoperative reduction in hemoglobin levels, adverse effects, bowel deflation time and time of postoperative hospital stay were compared. The procedure time, amount of hemorrhage and postoperative reduction in hemoglobin levels were not significantly different between the carboprost group and the vasopressin group (P>0.05). In the carboprost plus oxytocin group, the procedure time, amount of hemorrhage and postoperative reduction in hemoglobin levels were 24.3±2.6 min, 51.1±8.4 ml and 6.9±1.5 g/l, respectively, which were significantly less than those in the vasopressin and carboprost groups (all P<0.05). In the carboprost and carboprost plus oxytocin groups, the incidence of mild uterine contraction pain was significantly higher than in the vasopressin group (χ2=12.913, P=0.002). The incidences of other side‑effects were not significantly different among the three groups. The times for bowel deflation and postoperative hospital stay were marginally increased in both the carboprost and carboprost plus oxytocin groups, compared with the vasopressin group, although no significant differences were found among the three groups (P>0.05). Deep intramuscular injections of carboprost tromethamine prior to performing myomectomy could be an effective approach for reducing blood loss from intramural LM, in particular when combined with oxytocin intravenous infusion.
View Figures
View References

Related Articles

Journal Cover

September 2015
Volume 10 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, R., Shi, H., Ren, F., & Yuan, Z. (2015). Assessment of carboprost tromethamine for reducing hemorrhage in laparoscopic intramural myomectomy. Experimental and Therapeutic Medicine, 10, 1171-1174. https://doi.org/10.3892/etm.2015.2649
MLA
Zhang, R., Shi, H., Ren, F., Yuan, Z."Assessment of carboprost tromethamine for reducing hemorrhage in laparoscopic intramural myomectomy". Experimental and Therapeutic Medicine 10.3 (2015): 1171-1174.
Chicago
Zhang, R., Shi, H., Ren, F., Yuan, Z."Assessment of carboprost tromethamine for reducing hemorrhage in laparoscopic intramural myomectomy". Experimental and Therapeutic Medicine 10, no. 3 (2015): 1171-1174. https://doi.org/10.3892/etm.2015.2649